All In Biotech

Drug Trial Radar · NCT05102006

A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors

A Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LBL-007 in Combination With Toripalimab in the Treatment of Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Jun 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Nov 30, 2021

Primary completion

May 22, 2024

Study completion May 22, 2024

Sponsor

Lead sponsor
Nanjing Leads Biolabs Co.,LtdIndustry
Sponsor type
Industry
First posted
Nov 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, open-label, multicenter Phase Ib/II clinical study to evaluate the safety, tolerability, PK characteristics, immunogenicity and efficacy of LBL-007 in combination with Toripalimab in Treatment of Advanced Malignant Tumors.

Conditions

  • Advanced Malignant Tumors

Interventions

  • LBL-007 InjectionDrug

    LBL-007 Injection; dose A or dose B; Q3W

  • Toripalimab InjectionDrug

    Toripalimab Injection; dose C; Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30+7 days after drug withdrawal or before the start of new anti-tumor therapy)
  2. Dose-limiting toxicities(DLT)Time frame: During the first Cycles(each cycle is 21 days)
  3. Maximum tolerated dose (MTD)Time frame: During the first Cycles(each cycle is 21 days)

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • The first affiliated hospital of bengbu medical University

    Bengbu, Anhui, China

  • Chongqing University Three gorges Hospital

    Chongqing, Chongqing Municipality, China

  • The 900 Hospital of the Joint Service Support Force of the People's Liberation Army of China

    Fuzhou, Fujian, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • The First People's Hospital of Yu Lin

    Yulin, Guangxi, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Changzhou Cancer Hospital

    Changzhou, Jiangsu, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Affiliated Hospital of Jining Medical University

    Jining, Shandong, China

  • Linyi Cancer Hospital

    Linyi, Shandong, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.